Explore

Trendline Trendline
UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies

UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies

UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies
Trendline Trendline
UCB to Acquire Candid Therapeutics, Expanding Immunology Pipeline with T-cell Engagers

UCB to Acquire Candid Therapeutics, Expanding Immunology Pipeline with T-cell Engagers

UCB to Acquire Candid Therapeutics, Expanding Immunology Pipeline with T-cell Engagers
Trendline Trendline
UCB Acquires Candid Therapeutics to Enhance Immunology Pipeline with T-cell Engagers

UCB Acquires Candid Therapeutics to Enhance Immunology Pipeline with T-cell Engagers

UCB Acquires Candid Therapeutics to Enhance Immunology Pipeline with T-cell Engagers
Trendline Trendline
Merck Ends Development of TROP ADC Amidst Strategic Pipeline Adjustments

Merck Ends Development of TROP ADC Amidst Strategic Pipeline Adjustments

Merck Ends Development of TROP ADC Amidst Strategic Pipeline Adjustments
Reuters Reuters
Big Pharma M&A set for mega year as patent expiries drive deal urgency

Big Pharma M&A set for mega year as patent expiries drive deal urgency

By Christy Santhosh and Sriparna Roy May 1 (Reuters) - Biotech dealmaking is on pace for a bumper year in 2026, with large drugmakers on an acquisition spree to boost their pipelines ahead of upcoming patent losses.
Trendline Trendline
Bambusa Therapeutics Completes Enrollment for Phase 1b/2a Trial of BBT001 for Atopic Dermatitis

Bambusa Therapeutics Completes Enrollment for Phase 1b/2a Trial of BBT001 for Atopic Dermatitis

Bambusa Therapeutics Completes Enrollment for Phase 1b/2a Trial of BBT001 for Atopic Dermatitis
Trendline Trendline
Esperion Therapeutics to be Acquired by ARCHIMED in $1.1 Billion Deal

Esperion Therapeutics to be Acquired by ARCHIMED in $1.1 Billion Deal

Esperion Therapeutics to be Acquired by ARCHIMED in $1.1 Billion Deal
Trendline Trendline
Eli Lilly CEO David Ricks Discusses Quarterly Earnings and New Product Launch

Eli Lilly CEO David Ricks Discusses Quarterly Earnings and New Product Launch

Eli Lilly CEO David Ricks Discusses Quarterly Earnings and New Product Launch
Trendline Trendline
Ionis Pharmaceuticals to Participate in Major Healthcare Investor Conferences

Ionis Pharmaceuticals to Participate in Major Healthcare Investor Conferences

Ionis Pharmaceuticals to Participate in Major Healthcare Investor Conferences
Trendline Trendline
Bambusa Therapeutics Completes Enrollment for Atopic Dermatitis Drug Trial

Bambusa Therapeutics Completes Enrollment for Atopic Dermatitis Drug Trial

Bambusa Therapeutics Completes Enrollment for Atopic Dermatitis Drug Trial
Trendline Trendline
Summit Therapeutics Reports Q1 Financials and Progress in Cancer Drug Trials

Summit Therapeutics Reports Q1 Financials and Progress in Cancer Drug Trials

Summit Therapeutics Reports Q1 Financials and Progress in Cancer Drug Trials
Trendline Trendline
Novartis Unveils North Carolina API Plant as Part of $23 Billion U.S. Expansion

Novartis Unveils North Carolina API Plant as Part of $23 Billion U.S. Expansion

Novartis Unveils North Carolina API Plant as Part of $23 Billion U.S. Expansion